Rasio cepet Acumen Pharmaceuticals (ABOS)

The price history of Acumen Pharmaceuticals (ABOS) on the GURU.Markets platform is currently at 1.91. The business relies on exclusive antibody patents, overcoming the colossal costs and risks associated with clinical trials. Acumen Pharmaceuticals (ABOS) seeks market dominance through the development of ACU193 to combat Alzheimer's. Leading US clinics provide the patient inflow under strict FDA oversight.

This indicator measures immediate solvency by comparing cash and accounts receivable against short-term liabilities, excluding inventory. An analysis of the quick ratio allows for an assessment of the financial stability of Acumen Pharmaceuticals (ABOS) within the antibody development cycle, where the absence of inventory makes this calculation decisive for securing ongoing clinical trials.